Ranibizumab

Drug Profile

Ranibizumab

Alternative Names: AMD Fab - Genentech; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; rhuFab V2; rhuFab V2 AMD; VEGF antibody fragment

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Genentech; Manhattan Eye, Ear & Throat Hospital; Novartis Ophthalmics; University of Bonn
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Phase III Retinopathy of prematurity
  • Discontinued Retinal telangiectasis

Most Recent Events

  • 17 Apr 2017 Ranibizumab receives priority review status for Diabetic retinopathy without diabetic macular oedema in USA before April 2017
  • 17 Apr 2017 US FDA approves ranibizumab for treatment of all forms of Diabetic retinopathy in USA
  • 17 Apr 2017 Efficacy data from the phase III Protocol S trial in Diabetic retinopathy released by Genentech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top